Moderna touts research progress as it cuts R&D spending by $1.1 billion

Taking stock of the drug industry, from the lab to the medicine chest

September 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ruby Wallau for STAT STAT+ | Moderna touts research progress as it cuts R&D spending by $1.1 billion After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines. By Matthew Herper and Jason Mast STAT+ | A rare disease program, portrayed as both lifeline and pharma handout, is set to expire Advocates for people with rare diseases say a voucher program has been essential for attracting investment. Others call it a pharma handout. By Jason Mast and John Wilkerson STAT+ | Gilead's twice-yearly antiviral protects against HIV infection in second large trial Gilead's twice-yearly antiviral, lenacapavir, protected against HIV infection in a study that paves the way for FDA approval. By Elaine Chen Adobe STAT+ | Opinion: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma Pursuing a similar solutions-oriented path for biomanufacturing can address security concerns while strengthening domestic supply chains. By Kendalle Burlin O'Connell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser